Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Technique Treats Aggressive Brain Tumors by Disrupting Blood-Brain Barrier

By HospiMedica International staff writers
Posted on 18 Jul 2024

Glioblastoma, the most common malignant brain tumor, accounts for more than half of all such cancers. More...

Despite the use of aggressive treatments like surgery, chemotherapy, and radiotherapy, the prognosis for patients remains poor. A significant obstacle is the blood-brain barrier (BBB), which protects the brain from potential toxins in the bloodstream but also prevents many therapeutic agents from reaching brain tumors. This barrier highlights the urgent need for innovative treatments that can effectively target brain tumors like glioblastoma. Now, groundbreaking new research is exploring a new option that could one day be used to target glioblastoma and help add another tool to the cancer-fighting arsenal.

A team from Georgia Tech (Atlanta, GA, USA) and Virginia Tech (Blacksburg, VA, USA) previously conducted research on high frequency irreversible electroporation, or H-FIRE. H-FIRE utilizes non-thermal electrical pulses to destroy cancer cells and has been shown to disrupt the blood-brain barrier to enhance drug delivery. However, the study published in a paper in APL Bioengineering in May was the first to use a sinusoidal wave known as burst sine wave electroporation (B-SWE) to disrupt the blood-brain barrier. In a study using a rodent model to compare the impact of the sinusoidal wave against the more conventional, square-shaped wave, the researchers found that B-SWE resulted in less damage to cells and tissue but more disruption of the blood-brain barrier.

In certain clinical cases, both ablation and blood-brain barrier disruption would be ideal, but in other situations, blood-brain barrier disruption could be more important than destroying cells. For instance, in scenarios where a surgeon has removed the bulk of a tumor, B-SWE could potentially break down the blood-brain barrier around the surgical site, allowing chemotherapy agents to target any remaining cancer cells with minimal damage to the brain. The study also uncovered a drawback: the sinusoidal wave caused increased neuromuscular contractions, potentially harming the surrounding tissues. However, adjustments to the dosage of B-SWE showed it was possible to reduce these contractions while maintaining effective blood-brain barrier disruption. Future research aims to apply B-SWE to animal models with brain cancer to further explore its efficacy compared to the established H-FIRE technique in a clinical setting.

Related Links:
Georgia Tech
Virginia Tech


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.